E. Boersma, N. Er-cado, D. Oldermans, M. Gar-dien, J. et al., Acute myocardial infarction, The Lancet, vol.361, issue.9360, pp.847-858, 2003.
DOI : 10.1016/S0140-6736(03)12712-2

R. Beaglehole, R. Saracci, and S. Panico, Editorial -- Cardiovascular diseases: causes, surveillance and prevention, International Journal of Epidemiology, vol.30, issue.suppl 1, pp.1-4, 2001.
DOI : 10.1093/ije/30.suppl_1.S1

D. B. Baruah, R. N. Dash, M. R. Chaudhari, and S. S. Kadam, Plasminogen activators: A comparison, Vascular Pharmacology, vol.44, issue.1, pp.1-9, 2006.
DOI : 10.1016/j.vph.2005.09.003

S. M. Camiolo, S. Thorsen, and T. Astrup, Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin, and Plasmin, Experimental Biology and Medicine, vol.138, issue.1, pp.277-280, 1971.
DOI : 10.3181/00379727-138-35878

D. C. Rijken, Relationships between structure and function of tissue-type plasminogen activator, Klinische Wochenschrift, vol.66, pp.33-39, 1988.

J. Kuiper, A. Van-'t-hof, M. Otter, E. A. Biessen, D. C. Rijken et al., Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions, Biochemical Journal, vol.313, issue.3, pp.775-780, 1996.
DOI : 10.1042/bj3130775

J. J. E-m-e-i-s and C. , M .v a nd e nH o o g e n ,a n dD .J e n s e , " H e p a t i c clearance of tissue-type plasminogen activator in rats, Thrombosis and Haemostasis, vol.54, issue.3, pp.661-664, 1985.
URL : https://hal.archives-ouvertes.fr/in2p3-00277323

A. Hotchkiss, C. J. Refino, and C. K. Leonard, The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator, Thrombosis and Haemostasis, vol.60, issue.2, pp.255-261, 1988.

D. Pennica, W. E. Holmes, and W. J. Kohr, Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli, Nature, vol.2, issue.5897, pp.214-221, 1983.
DOI : 10.1038/301214a0

C. Philippe, Biotechnology for cardiovascular diseases, 2007.

W. D. Weaver, The role of thrombolytic drugs in the management of myocardial infarction: Comparative clinical trials, European Heart Journal, vol.17, issue.suppl F, pp.9-15, 1996.
DOI : 10.1093/eurheartj/17.suppl_F.9

K. Bailey, F. R. Bettelheim, L. Lorand, and W. R. Middlebrook, Action of Thrombin in the Clotting of Fibrinogen, Nature, vol.166, issue.4241, pp.233-234, 1951.
DOI : 10.1016/0006-3002(48)90016-X

N. Hasegawa and S. Sasaki, Location of the binding site ???b??? for lateral polymerization of fibrin, Thrombosis Research, vol.57, issue.2, pp.183-195, 1990.
DOI : 10.1016/0049-3848(90)90318-7

B. V. Pandya, J. L. Gabriel, J. O-'brien, and A. Z. Budzynski, Polymerization site in the .beta. chain of fibrin: mapping of the B.beta.1-55 sequence, Biochemistry, vol.30, issue.1, pp.162-168, 1991.
DOI : 10.1021/bi00215a024

J. Jiao, M. Yu, and B. Ru, Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1546, issue.2, pp.399-405, 2001.
DOI : 10.1016/S0167-4838(01)00161-3

G. Deleage and B. Roux, An algorithm for protein secondary structure prediction based on class prediction, "Protein Engineering, Design and Selection", vol.1, issue.4, pp.289-294, 1987.
DOI : 10.1093/protein/1.4.289
URL : https://hal.archives-ouvertes.fr/hal-00313814

M. Soleimani, F. Mahboudi, and N. Davoudi, Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae, Biotechnology and Applied Biochemistry, vol.48, issue.1, pp.55-61, 2007.

C. Heussen and E. B. Dowdle, Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates, Analytical Biochemistry, vol.102, issue.1, pp.196-202, 1980.
DOI : 10.1016/0003-2697(80)90338-3

A. Van-zonneveld, H. Veerman, H. Pannekoek, M. Nesheim, J. C. Fredenburgh et al., On the interaction of the finger and the kringle-2 domain of tissuetype plasminogen activator with fibrin. Inhibition of kringle- 2 binding to fibrin by ?-amino caproic acid The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant ? FEIX with intact fibrin, The Journal of Biological Chemistry The Journal of Biological Chemistry, vol.261, issue.265 35, pp.14214-14218, 1986.

D. L. Higgins and G. A. Vehar, Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin, Biochemistry, vol.26, issue.24, pp.7786-7791, 1987.
DOI : 10.1021/bi00398a038

D. J. Green-george, purified type I and type II t-PA, 1989.

U. Kohnert, R. Rudolph, and J. H. Verheijen, Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022, "Protein Engineering, Design and Selection", vol.5, issue.1, pp.93-100, 1992.
DOI : 10.1093/protein/5.1.93

J. M. Manosroi, Methods for large scale protein production in prokaryotes, p.40696, 2002.

G. N. Levine, M. N. Ali, and A. I. Schafer, Antithrombotic Therapy in Patients With Acute Coronary Syndromes, Archives of Internal Medicine, vol.161, issue.7, pp.937-948, 2001.
DOI : 10.1001/archinte.161.7.937

E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns et al., Intravenous Thrombolysis in Acute Myocardial Infarction, Chest, vol.119, issue.1, pp.253-277, 2001.
DOI : 10.1378/chest.119.1_suppl.253S

D. Russell, K. P. Madden, W. M. Clark, and J. A. Zivin, Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration, Stroke, vol.23, issue.3, pp.388-393, 1992.
DOI : 10.1161/01.STR.23.3.388

E. Topol, R. Califf, and F. Van-de-werf, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, The New England Journal of Medicine, vol.329, issue.10, pp.673-682, 1993.

D. Collen, Towards improved thrombolytic therapy The Lancet, pp.34-36, 1993.

N. Bhana and C. M. Spencer, Lanoteplase, BioDrugs, vol.1185, issue.2, pp.217-224, 2000.
DOI : 10.2165/00063030-200013030-00006

K. Ouriel, B. Katzen, and M. Mewissen, Reteplase in the Treatment of Peripheral Arterial and Venous Occlusions: A Pilot Study, Journal of Vascular and Interventional Radiology, vol.11, issue.7, pp.849-854, 2000.
DOI : 10.1016/S1051-0443(07)61799-0

A. Klausner, Researchers probe second generation t-PA, Biotechnology, vol.4, pp.706-711, 1986.

G. Noll, B. Lammle, and F. Duckert, Treatment with stanozolol before thrombolysis in patients with arterial occlusions, Thrombosis Research, vol.37, issue.4, pp.529-532, 1985.
DOI : 10.1016/0049-3848(85)90098-2

L. Q. Pierard-for-bioprocesses, R. E. S-p-i-e-r, and J. B. Griffiths, Secretion of recombinant hybrid plasminogen activator by mouse myeloma cells, Advances in Animal Cell Biology and Technology, pp.475-480, 1989.

T. Cartwright, R. E. S-p-i-e-r, J. B. G-r-i-ffiths, and J. , Production of t-PA from animal cell culture, Animal Cell Biotechnology

S. A. Rouf, M. Moo-young, and Y. Chisti, Tissue-type plasminogen activator: Characteristics, applications and production technology, Biotechnology Advances, vol.14, issue.3, pp.239-266, 1996.
DOI : 10.1016/0734-9750(96)00019-5

P. Bagchi, M. Mahesh, and R. Somashekhar, Pharmaco-Informatics: Homology Modelling of the Target Protein (GP1, 2) for Ebola Hemorrhagic Fever and Predicting an Ayurvedic Remediation of the Disease, Journal of Proteomics & Bioinformatics, vol.02, issue.07, pp.287-294, 2009.
DOI : 10.4172/jpb.1000088

A. Upshall, A. A. Kumar, and M. C. Bailey, Secretion of Active Human Tissue Plasminogen Activator from the Filamentous Fungus Aspergillus Nidulans, Bio/Technology, vol.33, issue.12, pp.1301-1304, 1987.
DOI : 10.1084/jem.148.1.223

R. V. Datar, T. Cartwright, and C. Rosen, Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator, Bio/Technology, vol.33, issue.3, pp.349-357, 1993.
DOI : 10.1146/annurev.bi.53.070184.002311

A. Lubiniecki, R. Arathoon, and G. Polastri, Selected strategies for manufacture and control of recombinant tissue plasminogen activator prepared from cell culture, Advances in Animal Cell Biology and Technology, pp.442-451, 1990.

J. F. Lemontt, C. M. Wei, and W. R. Dackowski, Expression of Active Human Uterine Tissue Plasminogen Activator in Yeast, DNA, vol.4, issue.6, pp.419-428, 1985.
DOI : 10.1089/dna.1985.4.419

J. B. Griffiths and A. Electricwala, Production of tissue plasminogen activators from animal cells, Advances in Biochemical Engineering, vol.34, pp.147-166, 1987.
DOI : 10.1007/BFb0000678

J. Manosroi, C. Tayapiwatana, F. Götz, R. G. Werner, and A. Manosroi, Secretion of Active Recombinant Human Tissue Plasminogen Activator Derivatives in Escherichia coli, Applied and Environmental Microbiology, vol.67, issue.6, pp.2657-2664, 2001.
DOI : 10.1128/AEM.67.6.2657-2664.2001

Y. Chisti and M. Moo-young, Separation techniques in industrial bioprocessing, Journal Institution of Chemical Engineers Symposium Series, vol.137, pp.135-146, 1994.

X. Li, Y. Qiu, and Y. Shen, Splicing together different regions of a gene by modified polymerase chain reaction-based site-directed mutagenesis, Analytical Biochemistry, vol.373, issue.2, pp.398-400, 2008.
DOI : 10.1016/j.ab.2007.10.021

P. Elliott, A. Hohmann, and J. Spanos, Protease expression in the supernatant of Chinese Hamster Ovary cells grown in serum-free culture, Biotechnology Letters, vol.25, issue.22, pp.1949-1952, 2003.
DOI : 10.1023/B:BILE.0000003992.09492.4b

G. Opdenakker, Protease inhibitors, a DNA construct for t h ee x p r e s s i o no fap r o t e a s ea n dap r o c e s sf o rm e a s u r i n g proteases and/or protease inhibitors, p.736302, 1996.